Prevention of Postoperative Delirium With Donepezil

• Status: Completed
• Trial end date: 2009-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Patients undergoing hip or knee joint replacement at the age of 70 years or above who are cognitively unimpaired will receive donepezil or matching placebo before (over 5-7 days), during and after (over 7 days) surgery. The incidence of delirium will be monitored at 3 days, 7 days, and 49 days following surgery. We hypothesize that the incidence of delirium can be lowered from 20 per cent to 10 per cent by the intervention.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Technische Universität München
• Collaborators: Eisai Deutschland; Eisai GmbH, Frankfurt, Germany
• Treatments: Donepezil

Criteria

Inclusion Criteria:

• Cognitively healthy, elective hip or knee replacement

Exclusion Criteria:

• Ongoing cholinergic treatment, dementia, delirium, acute physical illness